1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Circulating Tumor Cell Detection and Polyomavirus Status in Merkel Cell Carcinoma

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The incidence of Merkel cell carcinoma (MCC), a rare and highly metastatic skin malignancy, has sharply increased in the last decade. Clinical biomarkers are urgently needed for MCC prognosis, treatment response monitoring, and early diagnosis of relapse. The clinical interest of circulating tumors cells (CTCs) has been validated in many solid cancers. The aim of this study was to compare CTC detection and characterization in blood samples of patients with MCC using the CellSearch System and the RosetteSep -DEPArray workflow, an innovative procedure to enrich, detect and isolate single CTCs. In preliminary experiments (using spiked MCC cell lines) both methods allowed detecting very few MCC cells. In blood samples from 19 patients with MCC at different stages, CellSearch detected MCC CTCs in 26% of patients, and the R-D workflow in 42% of patients. The detection of CTC-positive patients increased to 52% by the cumulative positivity rate of both methodologies. Moreover, Merkel cell polyomavirus DNA, involved in MCC oncogenesis, was detected in tumor biopsies, but not in all single CTCs from the same patient, reflecting the tumor heterogeneity. Our data demonstrate the possibility to detect, isolate and characterize CTCs in patients with MCC using two complementary approaches.

          Related collections

          Most cited references27

          • Record: found
          • Abstract: found
          • Article: not found

          Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.

          A method for enumerating circulating tumor cells (CTC) has received regulatory clearance. The primary objective of this prospective study was to establish the relationship between posttreatment CTC count and overall survival (OS) in castration-resistant prostate cancer (CRPC). Secondary objectives included determining the prognostic utility of CTC measurement before initiating therapy, and the relationship of CTC to prostate-specific antigen (PSA) changes and OS at these and other time points. Blood was drawn from CRPC patients with progressive disease starting a new line of chemotherapy before treatment and monthly thereafter. Patients were stratified into predetermined Favorable or Unfavorable groups ( or =5 CTC/7.5mL). Two hundred thirty-one of 276 enrolled patients (84%) were evaluable. Patients with Unfavorable pretreatment CTC (57%) had shorter OS (median OS, 11.5 versus 21.7 months; Cox hazard ratio, 3.3; P 26 to 9.3 months). CTC are the most accurate and independent predictor of OS in CRPC. These data led to Food and Drug Administration clearance of this assay for the evaluation of CRPC.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Liquid biopsy and minimal residual disease — latest advances and implications for cure

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.

              Trials in castration-resistant prostate cancer (CRPC) need new clinical end points that are valid surrogates for survival. We evaluated circulating tumor cell (CTC) enumeration as a surrogate outcome measure.
                Bookmark

                Author and article information

                Contributors
                c-panabieres@chu-montpellier.fr
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                31 January 2020
                31 January 2020
                2020
                : 10
                : 1612
                Affiliations
                [1 ]GRID grid.466732.2, Laboratory of Rare Human Circulating Cells, , University Medical Centre of Montpellier, ; 34093 Montpellier, France
                [2 ]ISNI 0000 0001 2097 0141, GRID grid.121334.6, Pathogenesis and Control of Chronic Infections, , University of Montpellier, INSERM, EFS, University Medical Centre, ; 34090 Montpellier, France
                [3 ]ISNI 0000 0001 2097 0141, GRID grid.121334.6, Department of Dermatology, , University Medical Centre of Montpellier and INSERM 1058 Pathogenesis and Control of Chronic Infections University of Montpellier, ; 34090 Montpellier, France
                Article
                58572
                10.1038/s41598-020-58572-9
                6994658
                32005907
                77ecd437-65b9-4716-a2d6-5ccb0e6a099a
                © The Author(s) 2020

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 26 August 2019
                : 29 December 2019
                Funding
                Funded by: La ligue Contre le Cancer support Magali Boyer in a form of PhD studentship.
                Categories
                Article
                Custom metadata
                © The Author(s) 2020

                Uncategorized
                skin cancer
                Uncategorized
                skin cancer

                Comments

                Comment on this article